CoChat

Targeting the replication stress response in cancer

Forment, Josep V., O’Connor, Mark J. · 2018 · Pharmacology & Therapeutics
Cited by 156

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Many conventional chemotherapies used in cancer treatment exert their effect by inflicting DNA damage. Highly proliferative tissues, as well as tumour cells, are particularly vulnerable to this damage resulting in unwanted toxicities. In contrast, a targeted therapeutic approach has the aim of specifically eliminating cancer cells but with a reduced effect on healthy tissue. New therapies have been developed that target the replication stress response (RSR), a branch of the broader DNA damage response that specifically deals with interferences of the normal DNA replication program. Different pharmaceutical companies have developed inhibitors of the RSR kinases ATR, CHK1 and WEE1, which are currently at different phases of clinical development. Here, we review how the RSR works at the molecular level, what is the rationale for its targeting, and how we envisage its best use in the clinic, based on patient selection and combination therapies supported by in vitro and in vivo preclinical studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2018.03.005

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 106

  1. Aarts, 2012, Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1, Cancer Discovery, 2, 524, 10.1158/2159-8290.CD-11-0320 · DOI · Paper page
  2. Ammazzalorso, 2010, ATR and ATM differently regulate WRN to prevent DSBs at stalled replication forks and promote replication fork recovery, The EMBO Journal, 29, 3156, 10.1038/emboj.2010.205 · DOI · Paper page
  3. Apte, 2017, Life and cancer without telomerase: ALT and other strategies for making sure ends (don't) meet, Critical Reviews in Biochemistry and Molecular Biology, 52, 57, 10.1080/10409238.2016.1260090 · DOI
  4. Barlow, 2013, Identification of early replicating fragile sites that contribute to genome instability, Cell, 152, 620, 10.1016/j.cell.2013.01.006 · DOI · Paper page
  5. Barsanti, 2015, Structure-based drug design of novel, potent, and selective azabenzimidazoles (ABI) as ATR inhibitors, ACS Medicinal Chemistry Letters, 6, 42, 10.1021/ml500352s · DOI
  6. Beck, 2010, Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase, The Journal of Cell Biology, 188, 629, 10.1083/jcb.200905059 · DOI · Paper page
  7. Blackford, 2017, ATM, ATR, and DNA-PK: The trinity at the heart of the DNA damage response, Molecular Cell, 66, 801, 10.1016/j.molcel.2017.05.015 · DOI · Paper page
  8. Boguslawski, 1986, Characterization of monoclonal antibody to DNA.RNA and its application to immunodetection of hybrids, Journal of Immunological Methods, 89, 123, 10.1016/0022-1759(86)90040-2 · DOI · Paper page
  9. Booth, 2013, PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells, Cancer Biology & Therapy, 14, 458, 10.4161/cbt.24424 · DOI
  10. Bryant, 2014, Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human leukemia and lymphoma cells, Molecular Cancer, 13, 147, 10.1186/1476-4598-13-147 · DOI
  11. Buisson, 2017, APOBEC3A and APOBEC3B activities render cancer cells susceptible to ATR inhibition, Cancer Research, 77, 4567, 10.1158/0008-5472.CAN-16-3389 · DOI
  12. Bunting, 2010, 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks, Cell, 141, 243, 10.1016/j.cell.2010.03.012 · DOI · Paper page
  13. Carette, 2011, Global gene disruption in human cells to assign genes to phenotypes by deep sequencing, Nature Biotechnology, 29, 542, 10.1038/nbt.1857 · DOI · Paper page
  14. Carrassa, 2012, Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo, Cell Cycle, 11, 2507, 10.4161/cc.20899 · DOI
  15. Chen, 2015, ATR-mediated phosphorylation of FANCI regulates dormant origin firing in response to replication stress, Molecular Cell, 58, 323, 10.1016/j.molcel.2015.02.031 · DOI · Paper page
  16. Choi, 2016, ATM mutations in cancer: Therapeutic implications, Molecular Cancer Therapeutics, 15, 1781, 10.1158/1535-7163.MCT-15-0945 · DOI · Paper page
  17. Couch, 2013, ATR phosphorylates SMARCAL1 to prevent replication fork collapse, Genes & Development, 27, 1610, 10.1101/gad.214080.113 · DOI · Paper page
  18. D'Angiolella, 2012, Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair, Cell, 149, 1023, 10.1016/j.cell.2012.03.043 · DOI · Paper page
  19. Davies, 2011, Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation, Cancer Biology & Therapy, 12, 788, 10.4161/cbt.12.9.17673 · DOI
  20. Davoli, 2017, Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy, Science, 355, 10.1126/science.aaf8399 · DOI · Paper page
  21. Debatisse, 2012, Common fragile sites: Mechanisms of instability revisited, Trends in Genetics, 28, 22, 10.1016/j.tig.2011.10.003 · DOI · Paper page
  22. Deeg, 2016, Cancer cells with alternative lengthening of telomeres do not display a general hypersensitivity to ATR inhibition, Frontiers in Oncology, 6, 186, 10.3389/fonc.2016.00186 · DOI
  23. Dehe, 2017, Control of structure-specific endonucleases to maintain genome stability, Nature Reviews. Molecular Cell Biology, 18, 315, 10.1038/nrm.2016.177 · DOI · Paper page
  24. Desany, 1998, Recovery from DNA replicational stress is the essential function of the S-phase checkpoint pathway, Genes & Development, 12, 2956, 10.1101/gad.12.18.2956 · DOI · Paper page
  25. Dillon, 2017, Radiosensitization by the ATR inhibitor AZD6738 through generation of acentric micronuclei, Molecular Cancer Therapeutics, 16, 25, 10.1158/1535-7163.MCT-16-0239 · DOI
  26. Ding, 2016, Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies, Nature Communications, 7, 12425, 10.1038/ncomms12425 · DOI
  27. Dungrawala, 2015, The replication checkpoint prevents two types of fork collapse without regulating replisome stability, Molecular Cell, 59, 998, 10.1016/j.molcel.2015.07.030 · DOI · Paper page
  28. Fellmann, 2017, Cornerstones of CRISPR-Cas in drug discovery and therapy, Nature Reviews. Drug Discovery, 16, 89, 10.1038/nrd.2016.238 · DOI · Paper page
  29. Flynn, 2015, Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors, Science, 347, 273, 10.1126/science.1257216 · DOI · Paper page
  30. Fragkos, 2015, DNA replication origin activation in space and time, Nature Reviews. Molecular Cell Biology, 16, 360, 10.1038/nrm4002 · DOI · Paper page
  31. Gaillard, 2015, Replication stress and cancer, Nature Reviews. Cancer, 15, 276, 10.1038/nrc3916 · DOI · Paper page
  32. Gilad, 2010, Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner, Cancer Research, 70, 9693, 10.1158/0008-5472.CAN-10-2286 · DOI · Paper page
  33. Gotwals, 2017, Prospects for combining targeted and conventional cancer therapy with immunotherapy, Nature Reviews. Cancer, 17, 286, 10.1038/nrc.2017.17 · DOI · Paper page
  34. Green, 2017, Cytosine deaminase APOBEC3A sensitizes leukemia cells to inhibition of the DNA replication checkpoint, Cancer Research, 77, 4579, 10.1158/0008-5472.CAN-16-3394 · DOI
  35. Groth, 2007, Regulation of replication fork progression through histone supply and demand, Science, 318, 1928, 10.1126/science.1148992 · DOI · Paper page
  36. Guo, 2015, Interaction of Chk1 with treslin negatively regulates the initiation of chromosomal DNA replication, Molecular Cell, 57, 492, 10.1016/j.molcel.2014.12.003 · DOI
  37. Hanahan, 2011, Hallmarks of cancer: The next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  38. Harnor, 2017, Targeting DNA-dependent protein kinase for cancer therapy, ChemMedChem, 12, 895, 10.1002/cmdc.201700143 · DOI
  39. Harrigan, 2011, Replication stress induces 53BP1-containing OPT domains in G1 cells, The Journal of Cell Biology, 193, 97, 10.1083/jcb.201011083 · DOI · Paper page
  40. Hartford, 2016, Interaction with PALB2 is essential for maintenance of genomic integrity by BRCA2, PLoS Genetics, 12, 10.1371/journal.pgen.1006236 · DOI
  41. Heald, 1993, Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase, Cell, 74, 463, 10.1016/0092-8674(93)80048-J · DOI · Paper page
  42. Heijink, 2015, A haploid genetic screen identifies the G1/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity, Proceedings of the National Academy of Sciences of the United States of America, 112, 15160, 10.1073/pnas.1505283112 · DOI · Paper page
  43. Herrera-Abreu, 2016, Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer, Cancer Research, 76, 2301, 10.1158/0008-5472.CAN-15-0728 · DOI · Paper page
  44. Hoglund, 2011, Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells, Clinical Cancer Research, 17, 7067, 10.1158/1078-0432.CCR-11-1198 · DOI
  45. Kadoch, 2013, Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy, Nature Genetics, 45, 592, 10.1038/ng.2628 · DOI · Paper page
  46. Kim, 2017, Targeting the ATR/CHK1 Axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models, Clinical Cancer Research, 23, 3097, 10.1158/1078-0432.CCR-16-2273 · DOI · Paper page
  47. Kitagawa, 2004, Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway, Genes & Development, 18, 1423, 10.1101/gad.1200304 · DOI · Paper page
  48. Krajewska, 2015, ATR inhibition preferentially targets homologous recombination-deficient tumor cells, Oncogene, 34, 3474, 10.1038/onc.2014.276 · DOI
  49. Kuntz, 2009, The G(2) DNA damage checkpoint: Could this ancient regulator be the Achilles heel of cancer?, Cancer Biology & Therapy, 8, 1433, 10.4161/cbt.8.15.9081 · DOI
  50. Kwok, 2016, ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells, Blood, 127, 582, 10.1182/blood-2015-05-644872 · DOI · Paper page
  51. Lachaud, 2016, Ubiquitinated Fancd2 recruits Fan1 to stalled replication forks to prevent genome instability, Science, 351, 846, 10.1126/science.aad5634 · DOI
  52. Lam, 2014, RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma, Cancer Research, 74, 2193, 10.1158/0008-5472.CAN-13-1703 · DOI · Paper page
  53. Lam, 2004, Chk1 is haploinsufficient for multiple functions critical to tumor suppression, Cancer Cell, 6, 45, 10.1016/j.ccr.2004.06.015 · DOI · Paper page
  54. Lecona, 2014, Replication stress and cancer: It takes two to tango, Experimental Cell Research, 329, 26, 10.1016/j.yexcr.2014.09.019 · DOI · Paper page
  55. Ledermann, 2012, Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer, The New England Journal of Medicine, 366, 1382, 10.1056/NEJMoa1105535 · DOI · Paper page
  56. Ledermann, 2014, Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, The Lancet Oncology, 15, 852, 10.1016/S1470-2045(14)70228-1 · DOI · Paper page
  57. Liu, 2010, Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint, Nature, 467, 343, 10.1038/nature09350 · DOI · Paper page
  58. Lord, 2017, PARP inhibitors: Synthetic lethality in the clinic, Science, 355, 1152, 10.1126/science.aam7344 · DOI · Paper page
  59. Lossaint, 2013, FANCD2 binds MCM proteins and controls replisome function upon activation of s phase checkpoint signaling, Molecular Cell, 51, 678, 10.1016/j.molcel.2013.07.023 · DOI · Paper page
  60. Lujan, 2016, DNA polymerases divide the labor of genome replication, Trends in Cell Biology, 26, 640, 10.1016/j.tcb.2016.04.012 · DOI · Paper page
  61. Lukas, 2011, 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress, Nature Cell Biology, 13, 243, 10.1038/ncb2201 · DOI · Paper page
  62. Macheret, 2015, DNA replication stress as a hallmark of cancer, Annual Review of Pathology, 10, 425, 10.1146/annurev-pathol-012414-040424 · DOI · Paper page
  63. Mao, 2010, The human WRN and BLM RecQ helicases differentially regulate cell proliferation and survival after chemotherapeutic DNA damage, Cancer Research, 70, 6548, 10.1158/0008-5472.CAN-10-0475 · DOI
  64. Matthews, 2013, Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies, Expert Opinion on Drug Discovery, 8, 621, 10.1517/17460441.2013.788496 · DOI · Paper page
  65. Min, 2017, AZD6738, a novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells, Molecular Cancer Therapeutics, 16, 566, 10.1158/1535-7163.MCT-16-0378 · DOI
  66. Mir, 2010, In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma, Cancer Cell, 18, 244, 10.1016/j.ccr.2010.08.011 · DOI · Paper page
  67. Morgado-Palacin, 2016, Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML, Science Signaling, 9, ra91, 10.1126/scisignal.aad8243 · DOI
  68. Munoz, 2017, DNA replication stress: From molecular mechanisms to human disease, Chromosoma, 126, 1, 10.1007/s00412-016-0573-x · DOI
  69. Murga, 2011, Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors, Nature Structural & Molecular Biology, 18, 1331, 10.1038/nsmb.2189 · DOI · Paper page
  70. Neelsen, 2015, Replication fork reversal in eukaryotes: From dead end to dynamic response, Nature Reviews. Molecular Cell Biology, 16, 207, 10.1038/nrm3935 · DOI · Paper page
  71. Nieto-Soler, 2016, Efficacy of ATR inhibitors as single agents in Ewing sarcoma, Oncotarget, 7, 58759, 10.18632/oncotarget.11643 · DOI
  72. O'Connor, 2015, Targeting the DNA damage response in cancer, Molecular Cell, 60, 547, 10.1016/j.molcel.2015.10.040 · DOI · Paper page
  73. Otto, 2017, Cell cycle proteins as promising targets in cancer therapy, Nature Reviews. Cancer, 17, 93, 10.1038/nrc.2016.138 · DOI · Paper page
  74. Penna, 2017, Anti-mitotic agents: Are they emerging molecules for cancer treatment?, Pharmacology & Therapeutics, 173, 67, 10.1016/j.pharmthera.2017.02.007 · DOI
  75. Pfister, 2015, Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation, Cancer Cell, 28, 557, 10.1016/j.ccell.2015.09.015 · DOI · Paper page
  76. Pommier, 2016, Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action, Science Translational Medicine, 8, 10.1126/scitranslmed.aaf9246 · DOI · Paper page
  77. PosthumaDeBoer, 2011, WEE1 inhibition sensitizes osteosarcoma to radiotherapy, BMC Cancer, 11, 156, 10.1186/1471-2407-11-156 · DOI
  78. Prevo, 2012, The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy, Cancer Biology & Therapy, 13, 1072, 10.4161/cbt.21093 · DOI · Paper page
  79. Ragland, 2013, RNF4 and PLK1 are required for replication fork collapse in ATR-deficient cells, Genes & Development, 27, 2259, 10.1101/gad.223180.113 · DOI · Paper page
  80. Rajeshkumar, 2011, MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts, Clinical Cancer Research, 17, 2799, 10.1158/1078-0432.CCR-10-2580 · DOI · Paper page
  81. Ray Chaudhuri, 2016, Replication fork stability confers chemoresistance in BRCA-deficient cells, Nature, 535, 382, 10.1038/nature18325 · DOI · Paper page
  82. Ruiz, 2016, A genome-wide CRISPR screen identifies CDC25A as a determinant of sensitivity to ATR inhibitors, Molecular Cell, 62, 307, 10.1016/j.molcel.2016.03.006 · DOI · Paper page
  83. Russell, 2013, Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma, Cancer Research, 73, 776, 10.1158/0008-5472.CAN-12-2669 · DOI
  84. Ruzankina, 2007, Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss, Cell Stem Cell, 1, 113, 10.1016/j.stem.2007.03.002 · DOI · Paper page
  85. Saldivar, 2017, The essential kinase ATR: Ensuring faithful duplication of a challenging genome, Nature Reviews. Molecular Cell Biology, 18, 622, 10.1038/nrm.2017.67 · DOI · Paper page
  86. Sanjiv, 2016, Cancer-specific synthetic lethality between ATR and CHK1 kinase activities, Cell Reports, 17, 3407, 10.1016/j.celrep.2016.12.031 · DOI
  87. Santos-Pereira, 2015, R loops: New modulators of genome dynamics and function, Nature Reviews. Genetics, 16, 583, 10.1038/nrg3961 · DOI · Paper page
  88. Sarmento, 2015, CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress, Oncogene, 34, 2978, 10.1038/onc.2014.248 · DOI
  89. Schlacher, 2011, Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11, Cell, 145, 529, 10.1016/j.cell.2011.03.041 · DOI · Paper page
  90. Schoppy, 2012, Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR, The Journal of Clinical Investigation, 122, 241, 10.1172/JCI58928 · DOI · Paper page
  91. Sen, 2017, Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small cell lung cancer, Clinical Cancer Research, 23, 6239, 10.1158/1078-0432.CCR-17-1284 · DOI · Paper page
  92. Sen, 2017, CHK1 inhibition in small cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib, Cancer Research, 77, 3870, 10.1158/0008-5472.CAN-16-3409 · DOI · Paper page
  93. Shaltiel, 2015, The same, only different - DNA damage checkpoints and their reversal throughout the cell cycle, Journal of Cell Science, 128, 607, 10.1242/jcs.163766 · DOI · Paper page
  94. Shen, 2015, Genome-derived cytosolic DNA mediates type I interferon-dependent rejection of B cell lymphoma cells, Cell Reports, 11, 460, 10.1016/j.celrep.2015.03.041 · DOI · Paper page
  95. Somyajit, 2015, Mammalian RAD51 paralogs protect nascent DNA at stalled forks and mediate replication restart, Nucleic Acids Research, 43, 9835
  96. Stingele, 2017, Mechanisms of DNA-protein crosslink repair, Nature Reviews. Molecular Cell Biology, 18, 563, 10.1038/nrm.2017.56 · DOI · Paper page
  97. Techer, 2017, The impact of replication stress on replication dynamics and DNA damage in vertebrate cells, Nature Reviews. Genetics, 18, 535, 10.1038/nrg.2017.46 · DOI · Paper page
  98. Toledo, 2017, Replication Catastrophe: When a checkpoint fails because of exhaustion, Molecular Cell, 66, 735, 10.1016/j.molcel.2017.05.001 · DOI · Paper page
  99. Toledo, 2011, Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs, Molecular Oncology, 5, 368, 10.1016/j.molonc.2011.07.002 · DOI · Paper page
  100. Tsimberidou, 2015, Targeted therapy in cancer, Cancer Chemotherapy and Pharmacology, 76, 1113, 10.1007/s00280-015-2861-1 · DOI · Paper page
  101. Vendetti, 2015, The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo, Oncotarget, 6, 44289, 10.18632/oncotarget.6247 · DOI · Paper page
  102. Weisberg, 2015, Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies, Leukemia, 29, 27, 10.1038/leu.2014.149 · DOI
  103. Wolf, 2016, RPA and Rad51 constitute a cell intrinsic mechanism to protect the cytosol from self DNA, Nature Communications, 7, 11752, 10.1038/ncomms11752 · DOI · Paper page
  104. Yazinski, 2017, ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells, Genes & Development, 31, 318, 10.1101/gad.290957.116 · DOI · Paper page
  105. Yin, 2017, Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer, American Journal of Cancer Research, 7, 473
  106. Zabludoff, 2008, AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies, Molecular Cancer Therapeutics, 7, 2955, 10.1158/1535-7163.MCT-08-0492 · DOI · Paper page

Cited by

See all 156

Metadata

Authors
Forment, J. V., & O’Connor, M. J.
Venue
Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
2018-08
Volume
188
Pages
155-167
ISSN
0163-7258 (ISSN-L)
OpenAlex
W2790769350
Cited by
156
References
19
FWCI
6.91
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.